US health officials advance plan for peptide access favored by RFK Jr.

U.S. health officials are advancing a plan to permit specialty pharmacies to produce specific peptides, a class of largely unregulated injections that have gained popularity among followers of Health Secretary Robert F. Kennedy Jr. and other wellness influencers.

Interim Access Policy Submitted

According to a posting on a government website, Kennedy’s Department of Health and Human Services (HHS) submitted a peptides “interim access policy” to the White House for review. The plan was sent to the Office of Management and Budget, which reviews federal rules and regulations with the potential for significant economic impact. HHS officials did not immediately respond to requests for comment.

The policy is intended to allow pharmacies to temporarily compound some of the most popular peptides, including BPC-157, a chemical promoted to build muscle and heal injuries. Two people familiar with the plan, who spoke on condition of anonymity to discuss confidential government deliberations, stated that the approach is known as enforcement discretion. This allows the Food and Drug Administration (FDA) to selectively choose not to enforce some of its own regulations, essentially assuring compounding pharmacies that they will not be targeted for producing certain peptides.

Regulatory Context and Safety Concerns

Peptides are the building blocks of more complex proteins, triggering hormones inside the body needed for growth, metabolism and healing. While drug companies have brought several peptides to market as medications for diabetes and weight loss, the specific peptides at issue in this plan have not gone through the rigorous vetting process required for FDA approval. Most data on these substances comes from animal studies, and their uses for bulking up, looking younger, or boosting energy are not approved by the FDA.

Previously, the FDA placed BPC-157 and more than a dozen other injectable peptides on its list of substances that are too risky to be compounded by pharmacies. According to the FDA, possible risks include contamination, allergic reactions and tumor growth.

However, earlier this year, Kennedy directed the agency to reconsider a short list of chemicals widely promoted by wellness influencers. In July, a panel of external FDA advisers recommended the agency drop its restrictions on six of the seven peptides put before them. This recommendation went against the scientific conclusion of FDA’s staff scientists, who reiterated that none of the peptides had been studied enough to establish their safety and effectiveness.

Market Impact and Political Support

The proposal has been praised by some Kennedy allies who sell peptides. Brigham Buhler, a wellness clinic operator who sells peptides through an online service, posted on X: “This is huge.” He added, “This isn’t about whether you’re for or against peptides. It’s about whether you’re for or against MEDICAL FREEDOM.”

The peptide business has attracted attention from major telehealth providers, including Hims & Hers and Noom. Both companies recently announced plans to offer peptides to their customers if the federal government eases access. Wall Street analysts estimate the market could be worth $2 billion to $3 billion.

Before joining the administration, Kennedy publicly declared that “FDA’s war” on peptides and other wellness products would soon end. After becoming health secretary, he stated that U.S. compounding pharmacies must be allowed to sell peptides because Americans were increasingly turning to “gray market” peptides made in China and other countries.

Why it matters

This development marks a significant shift in federal regulatory posture toward unproven wellness products. By using enforcement discretion rather than formal rulemaking, the administration can bypass the lengthy process of adding peptides to the FDA's list of drugs safe for compounding, which could take years and involve multiple rounds of public comment. The move aligns with the goals of the Make America Healthy Again movement, which has pushed for easier access to these substances despite warnings from FDA staff scientists regarding their safety and efficacy.

---

Sources

• thestar.com: Trump administration advances plan for peptide drugs favored by RFK Jr.
• nhregister.com: Trump administration advances plan for peptide drugs favored by RFK Jr.
• eagletribune.com: Trump administration advances plan for peptide drugs favored by RFK Jr. | Region | eagletribune.com

This article was drafted with AI assistance and checked against the sources above. Company claims are reported as claims. Cover image is AI-generated.